ERBB2 and breast neoplasm: Another complicating factor is that HR+/HER2+ breast tumors are heterogeneous at a molecular level and HR status does not completely recapitulate this heterogeneity: 40-50% of these tumors belong to HER2-enriched PAM50 molecular subtype, while the rest are classified as luminal A or B subtype [10, 11].